Mekinist (trametinib) — Medica

Initial criteria

• Patient has unresectable, advanced (including Stage III or Stage IV disease), or metastatic melanoma
• Patient meets ONE of the following (i or ii): i) Patient has BRAF mutation-positive disease; OR ii) Patient has BRAF fusion-positive disease

Approval duration

1 year